Bio-rad Laboratories Stock News

Strength in Life Sciences segment driven by a recovery in routine testing drove Bio-Rad (BIO) top line in the fourth quarter.

Bio Rad Laboratories, Inc. (BIO) CEO Norman Schwartz on Q4 2021 Results - Earnings Call Transcript

HERCULES, Calif.--(BUSINESS WIRE)--Bio-Rad Laboratories, Inc. (NYSE: BIO and BIOb), a global leader of life science research and clinical diagnostic products, today announced financial results for the fourth quarter and year ended December 31, 2021. Fourth-quarter 2021 net sales were $732.8 million, a decrease of 7.2 percent compared to $789.8 million reported for the fourth quarter of 2020. On a currency-neutral basis, quarterly sales decreased 6.9 percent compared to the same period in 2020.

Bio-Rad (BIO) delivered earnings and revenue surprises of 11.85% and 0.59%, respectively, for the quarter ended December 2021. Do the numbers hold clues to what lies ahead for the stock?

Investors are optimistic about Bio-Rad's (BIO) strong growth within Life Science and Clinical Diagnostics segments across all regions.

Bio Rad's (BIO) strength in its key product lines across major geographic regions buoys optimism.

PUNE, India, Jan. 11, 2022 (GLOBE NEWSWIRE) -- Global Next Generation Sequencing (NGS) Market is growing with a CAGR of 17.1% in the forecast period of 2022 to 2029 and is expected to reach USD 29,307.13 Million by 2029. The most appropriate, exclusive, realistic, and admirable Next Generation Sequencing (NGS) Market Research Report is delivered with devotion depending upon the business needs. With the precise base year and the historic year, estimations and calculations are performed in this industry report. Market share analysis and key trend analysis are the key accomplishing factors in this market report. Report helps to recognize how the market is going to perform in the forecast years by giving information about market definition, classifications, applications, and engagements. DBMR team provides Next Generation Sequencing (NGS) Market research report with loyalty that is promising and the way in which expected. Get Sample Report + All Related Graphs & Charts @ https://www.databridgemarketresearch.com/request-a-sample/?dbmr=global-next-generation-sequencing-ngs-market Key Companies operating in the Next Generation Sequencing (NGS) Market are: Agilent Technologies Inc Thermo Fisher Scientific Inc QIAGEN Illumina Inc Bio-Rad Laboratories Inc Roche Sequencing (A subsidiary of F.

Investors are keenly aware that growth stocks have beaten value stocks five years in a row. So what am I going to recommend today?

Investors are optimistic about Bio-Rad (BIO) owing to robust segmental performances and a rebound in non-COVID businesses.

Bio-Rad Laboratories continues to report impressive earnings and has been on a winning streak with nearly two years of strong beats on EPS and revenue. The company's expansive product portfolio has fa

Nelson Van Denburg & Campbell Wealth Management Group LLC lessened its position in shares of Bio-Rad Laboratories, Inc. (NYSE:BIO) by 16.1% during the 3rd quarter, according to the company in its most recent 13F filing with the SEC. The fund owned 1,208 shares of the medical research companys stock after selling 231 shares during the []